Drugs / human recombined granulocyte-macrophage colony stimulating factor
last change Dec 2019 re-read 2 minutes ago

human recombined granulocyte-macrophage colony stimulating factor

Developed for
lung cancer
Investigated by
The First Affiliated Hospital of Xiamen University

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02976740 Nov 2016 → Jun 2019 lung cancer The First Affiliated Hospital of Xiamen University Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as human recombined granulocyte-macrophage colony stimulating factor “Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle.” NCT02976740
Route Subcutaneous Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day)” NCT02976740